Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar. Visual acuity outcomes were similar between ...

Please provide your email address to receive an email when new articles are posted on . SEATTLE — In eyes with center-involved diabetic macular edema, using bevacizumab first and switching to ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K.

The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care for previously untreated metastatic colorectal cancer. Continuation of bevacizumab beyond progression is an ...

The addition of bevacizumab (Avastin) to chemotherapy for the treatment of metastatic colorectal cancer may not be cost-effective, according to a report from Gastroenterology & Endoscopy News.

TOKYO/LONDON, May 30 (Reuters) - Japan set a lower-than-expected price for cancer drug Avastin, sending shares of Roche's partner Chugai Pharmaceutical <4519.T> down 7 percent and underscoring ...

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma A cost-effectiveness analysis compared the three arms of the Gynecologic Oncology Group (GOG) 218 study ...

LONDON, Aug 24 (Reuters) - Britain's healthcare cost agency NICE rejected Roche's drug Avastin for advanced bowel cancer again on Tuesday, saying it was too expensive, despite a fresh price deal ...